| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.048 | 0.4 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.041 | 0.4 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.14 | 0.4 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.047 | 0.4 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | UNC0638 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | -0.029 | 0.4 |